Mineral and bone disease under the three levers: osteoporosis, hyperparathyroidism, CKD-MBD

The owned mineral and bone diseases are read through the three-lever principle, selecting each disease’s primary lever from the corrupted OU parameter. Osteoporosis is a depleted reservoir treated anabolic-first (L2 before L1); hyperparathyroidism and ADH1 are setpoint drifts reset by calcimimetic / calcilytic (L3); CKD-MBD is a multi-arm gain failure needing three levers; humoral hypercalcemia is an external load (L1).

The mineral and bone diseases this volume owns — osteoporosis, primary hyperparathyroidism, autosomal dominant hypocalcemia, CKD-MBD with secondary hyperparathyroidism, humoral hypercalcemia of malignancy, and the magnesium disorders — are read here through the three levers. The method is principled, not descriptive: for each disease the PRIMARY lever is SELECTED from which Ornstein-Uhlenbeck parameter the disease corrupted (load, gain, or setpoint), demonstrated on the volume’s own OU law, and turned into an honestly-graded improvement proposal grounded in the inherited non-opioid analgesic technology (DOI 10.5281/zenodo.20733420) and the measured-γ gain ceiling. Owned means common, polygenic, acquired or age-related loop disorders; rare monogenic gene facts are cited to the rare-disease SSOT and not re-derived (VP_FRAMEWORK_MAP §6).

Selecting the lever from the corrupted parameter

The selection rule is mechanical and it prevents the most common therapeutic error — treating the symptom instead of the defended state. If the disease imposes an unsuppressible external LOAD, the matched lever is L1 (oppose the source). If it drops a LOOP GAIN — a failed transport arm or a depleted reservoir — the matched lever is L2 (restore or refill the gain). If it drifts the defended TARGET, the matched lever is L3 (recalibrate the comparator). Reading the corrupted parameter first is what tells you that alkali for an acidosis arm, plain calcium for a low set-point, or an anti-resorptive alone for a depleted reservoir each addresses the wrong parameter.

Osteoporosis: refill the gain before holding the drain (L2 before L1)

Osteoporosis is a depleted calcium reservoir with a low remodeling gain, so its primary lever is L2 — and the framework’s distinctive call is the SEQUENCE. On the volume’s own reservoir law, an untreated reserve starting half-full drifts DOWN (to 0.3296); an anti-resorptive holding the drain (L1) arrests the fall but does not refill (0.8499); an anabolic agent raising the remodeling gain (L2) refills toward full (1.0000). Anti-resorptive alone halts; only the gain lever rebuilds. The clinical reading is anabolic-FIRST — teriparatide or abaloparatide (intermittent PTH), romosozumab (anti-sclerostin) — to refill, THEN anti-resorptive — bisphosphonate, denosumab — to lock in. Refill the gain before holding the drain: a sequence call, not just a drug list. [V] L2 refills where L1 only halts; sequence and drugs [L]; absolute gains [O].

Primary hyperparathyroidism and ADH1: the setpoint has moved (L3)

In primary hyperparathyroidism the defended calcium set-point has drifted UP (autonomous PTH; the CaSR comparator is effectively reset high); in autosomal dominant hypocalcemia type 1 (ADH1) an activating CaSR senses calcium as high, so the set-point is held LOW. Both are setpoint diseases, and the OU law exposes the trap of treating them with symptom control: on the volume’s own setpoint-drift demonstration the defended value sits at 1.15 untreated, returns to 1.00 after an L3 reset, but springs back to 1.15 the moment a mere symptom control is withdrawn — the relapse signature of an unaddressed setpoint. The matched lever is L3: the calcimimetic cinacalcet resets the CaSR DOWN in hyperparathyroidism, the calcilytic encaleret resets it UP in ADH1 — durable allosteric recalibration. Parathyroidectomy is the L1 cure when the source is a single autonomous gland. [V] direction; drugs and surgery [L].

CKD-MBD: a multi-arm failure needs a multi-lever package

CKD-MBD with secondary hyperparathyroidism is the case where no single lever suffices. Nephron loss drops the loop gain across SEVERAL renal arms at once — the 1,25-vitamin-D arm, the phosphate-excretion arm, the calcium-handling arm — so the three levers must act together: L1 phosphate-load control (dietary restriction and binders), L2 active-vitamin-D arm substitution (calcitriol or paricalcitol replacing the failed renal hydroxylation), and L3 a calcimimetic on the driven PTH. This is not lever-stacking for its own sake; it is the matched response to a multi-arm gain failure, and it is why CKD-MBD resists any single-agent fix. [L] the three drug arms; [V] the multi-arm reading; [O] dosing.

Humoral hypercalcemia of malignancy and the magnesium disorders

Humoral hypercalcemia of malignancy is an unsuppressible external LOAD — tumor-secreted PTHrP that the CaSR cannot switch off — so its primary lever is L1: treat the tumor and oppose PTHrP. Hydration and anti-resorptives (bisphosphonate, denosumab) are symptom control that blunts the calcium release and buys time, but they do not touch the load at its source. The magnesium disorders are a loop-gain drop on a third defended ion — the magnesium reabsorption arm — so repletion holds the mean (L1) while arm restoration is the durable fix (L2), exactly the magnesium failure mode the disease-coverage chapter already derived from the same six modes. Across all six diseases the primary lever is read off the corrupted parameter, never guessed.